Olema Pharmaceuticals

Olema Pharmaceuticals

OLMA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +328.8% in FY2025

Sean Bohen, M.D., Ph.D. is the CEO of Olema Pharmaceuticals and was paid $3.2M in FY2025 (Dec), down 61%.

Pay$100 in the stock at the end of FY21 → $267
CEO pay is from each Olema Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Sean Bohen, M.D., Ph.D.FY2025
  2. 2Shawnte Mitchell, J.D.FY2025
  3. 3Shane KovacsFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Olema Pharmaceuticals paid its 3 named executives $7.1M in total in FY2025 (Dec). CEO Sean Bohen, M.D., Ph.D. was paid $3.2M of that.

Name
Sean Bohen, M.D., Ph.D.President and Chief Executive Officer
Shawnte Mitchell, J.D.Chief Legal Officer and Corporate SecretaryNot disclosed
Shane KovacsChief Operating and Financial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers28

See all

The FY2025 (Dec) proxy of Olema Pharmaceuticals names 28 peer companies for pay. Among Olema Pharmaceuticals and these peers, CEO pay was 13th highest of 15 and total shareholder return was the highest of 15.

13th highest of 15in Olema Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$2.3M$27.8M

1st highest of 15in Olema Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$14$1,020

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board5

See all
  • Cyrus L. HarmonDirector · 19 yr on the boardIndependentScience and Technology—Paid as an executive
  • Gorjan HrustanovicDirector · 7 yr on the boardIndependentCompensation, Science and Technology—Paid as an executive
  • Graham WalmsleyDirector · 5 yr on the boardIndependentAudit—Paid as an executive
  • Sandra J. HorningDirector · 5 yr on the boardIndependentNominating and Corporate Governance, Science and Technology (Chair)—Paid as an executive
  • Prakash RamanDirector · -1 yr on the boardIndependent—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

  1. Pay
    Olema Pharmaceuticals Chief Operating and Financial Officer pay fell 56% to $1.9M. The stock rose 329% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Olema Pharmaceuticals CEO pay fell 61% to $3.2M. The stock rose 329% in FY2025 (Dec).
    DEF 14A
  3. Board
    Prakash Raman joined the board of Olema Pharmaceuticals. Prakash Raman now sits on 2 public boards.
    3
  4. Pay
    Olema Pharmaceuticals Chief Operating and Financial Officer pay rose 176% to $4.3M. The stock fell 58% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Olema Pharmaceuticals CEO pay rose 158% to $8.1M. The stock fell 58% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Olema Pharmaceuticals Chief Medical Officer pay rose 129% to $3.0M. The stock fell 58% in FY2024 (Dec).
    DEF 14A
  7. Board
    Scott Garland joined the board of Olema Pharmaceuticals. Scott Garland now sits on 3 public boards.
    3
  8. Pay
    Olema Pharmaceuticals Chief Operating and Financial Officer pay fell 32% to $1.5M. The stock rose 473% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Olema Pharmaceuticals CEO pay fell 47% to $3.2M. The stock rose 473% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Olema Pharmaceuticals Chief Medical Officer pay fell 42% to $1.3M. The stock rose 473% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KMar 16, 2026FY2025
Proxy statementDEF 14AApr 28, 2025FY2024
Annual report10-KMar 18, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KMar 11, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data